Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2006

Las noticias de Madrid (News from Madrid)
Suzanne Elizabeth Wahrle
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Wahrle, Suzanne Elizabeth, ,"Las noticias de Madrid (News from Madrid)." Molecular Neurodegeneration.
1,. 10. (2006).
https://digitalcommons.wustl.edu/open_access_pubs/180

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Molecular Neurodegeneration

BioMed Central

Open Access

Meeting report

Las noticias de Madrid (News from Madrid)
Suzanne Elizabeth Wahrle*
Address: Department of Neurology, Washington University School of Medicine. Campus Box 8111, 660 S. Euclid Ave., St. Louis, MO 63110, USA
Email: Suzanne Elizabeth Wahrle* - wahrles@msnotes.wustl.edu
* Corresponding author

Published: 06 September 2006
Molecular Neurodegeneration 2006, 1:10

doi:10.1186/1750-1326-1-10

Received: 04 August 2006
Accepted: 06 September 2006

This article is available from: http://www.molecularneurodegeneration.com/content/1/1/10
© 2006 Wahrle; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
Over 5,000 participants attended the 10th International Conference on Alzheimer's Disease
(ICAD) and Related Disorders in Madrid, Spain from July 15–20, 2006. Highlights of the conference
included reports on brain imaging, the discovery of mutations in the progranulin gene that cause
frontotemporal dementia, the finding that neuregulin-1 is a substrate for BACE1 and new interest
in the connection between Alzheimer's disease and metabolic syndromes.

The 10th International Conference on Alzheimer's Disease
(ICAD) and Related Disorders was held in the Spanish
capitol of Madrid from July 15–20, 2006. More than
5,000 researchers, students and clinicians came to Madrid
to present their research and learn about the findings of
others. The welcome reception at Palacio Negralejo, a
sprawling estate on the outskirts of Madrid, allowed
attendees to meet collaborators and friends and sample
some typical Spanish food: Iberic ham, seafood paella,
grilled veal and various tapas. Flamenco dancers, banjo
players, and plenty of sangria created a festive beginning
for the conference.
The main conference was preceded by an imaging consortium on Alzheimer's disease (AD). Using a wide variety of
methods, investigators showed correlations between AD
or aging and different imaging measures. There was particular interest in white matter lesions, which several scientists noted were closely correlated with AD. Frank-Erik De
Leeuw from UMC-Stradboud in the Netherlands reported
that the extent of white matter lesions correlates with
medial temporal atrophy in late-onset but not early-onset
AD, suggesting that late-onset and early-onset AD may
have some different pathological pathways [1]. There
were also several reports on brain PET imaging using the

Pittsburgh compound B (PiB). William Klunk from the
University of Pittsburgh estimated that over 500 patients
at 12 institutions have undergone PET scans using PiB,
which appears to be a reliable marker of amyloid deposition [2]. It is hoped that imaging will identify patients at
risk for AD and differentiate patients with amyloid-β deposition from patients with other types of pathology.
Although there were hundreds of presentations at ICAD, a
few stood out because of their importance and novelty.
Perhaps the biggest news came from two independent
groups of researchers at the Mayo Clinic and the University of Antwerp in Belgium. Both groups found mutations
in the gene encoding progranulin that cause a form of
frontotemporal dementia (FTD), the second most common form of dementia in individuals younger than 65
years old [3,4]. Since 1998, when mutations in the microtubule-associated protein tau (MAPT) gene on chromosome 17 were found to cause FTD with parkinsonism,
geneticists have been stymied by families with FTD linked
to the same region on chromosome 17 but having no
MAPT mutations. It seemed likely that difficult-to-find
mutations in MAPT accounted for these FTD cases, but the
mutations could not be found despite heroic efforts.
Geneticists then sequenced genes near MAPT and were
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rewarded by finding mutations in the progranulin gene
(PGRN), which is located a mere 1.7 Mb away from
MAPT. In one patient series, PGRN mutations accounted
for at least 11% of all FTD cases and 26% of familial FTD
cases. Interestingly, all the PRGN mutations that were
reported are dominant and effectively create null alleles,
meaning that the FTD phenotype results from decreased
levels of progranulin in affected individuals. Additionally,
the ubiquitin-positive inclusions in the brains of affected
individuals do not stain with anti-progranulin antibodies,
leaving the identity of the ubiquitinated protein an
intriguing mystery. The discovery of PGRN mutations is a
major advance in our understanding of FTD and will
undoubtedly inspire intense research to discover the
mechanism by which progranulin deficiency leads to FTD.
Another interesting story from the conference involved
BACE1, the major β-secretase in the brain. Sequential
cleavage of amyloid precursor protein by β-secretase and
then γ-secretase produces the amyloid β-peptide (Aβ).
Since inhibition of β-secretase should decrease Aβ levels
in the brain, it is an attractive therapeutic target. In fact,
Martin Citron from Amgen reported that over 100 patents
have been filed for BACE1 inhibitors [5]. However, inhibition of BACE1 could have negative consequences if
other molecules that are physiologically important
require cleavage by BACE1. Christian Haass and his colleagues in Germany were attempting to find normal substrates for BACE1 and began with two key observations: 1.
BACE1 expression is high post-natally but low in adults
and 2. BACE1 is not expressed by invertebrates. From
these clues, Haass and his colleagues thought that BACE1
may be involved in myelination, which is prominent in
the post-natal time interval and is not present in invertebrates. Their hypothesis was correct: electron microscopic
examination of the peripheral nerves from BACE1 deficient mice showed pronounced hypomyelination [6].
Interestingly, this hypomyelination phenotype was similar to that of neuregulin-1 haploinsufficient mice, which
led Haass and his colleagues to hypothesize that neuregulin-1 was a substrate for BACE1. Next they found that neuregulin-1 levels are elevated in the brains of Bace1-/- mice,
most likely because BACE1 is the major enzyme that
cleaves neuregulin-1. Finally, they demonstrated that neuregulin-1 is cleaved by BACE1 in vitro [7]. It is unknown
whether inhibition of neuregulin-1 cleavage in adults, as
could occur with the therapeutic usage of BACE1 inhibitors, would create adverse effects. Since myelination primarily occurs in childhood, decreased neuregulin-1
cleavage in older adults may not be an issue, but this
remains to be proven. Overall, this was a remarkable story
because the investigators deduced such a large amount of
information from two seemingly small observations.
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An area that has not been previously emphasized, the
interaction between AD and metabolic syndromes such as
obesity and diabetes, was discussed in multiple sessions.
Miia Kivipelto from the Stockholm Gerontology Research
Center presented epidemiological data showing that obesity, hypercholesterolemia and hypertension were all risk
factors for AD and that when all three factors were present
in the same individual the risk of AD increased 6-fold [8].
Other investigators found links between diabetes, peripheral insulin resistance, cerebral glucose metabolism and
cognitive dysfunction, but the mechanisms involved were
not clear. However, a possible connection between AD
and metabolic syndromes has important therapeutic
implications. Previous studies have shown that intravenous (IV) insulin administration improves cognition in
AD patients, but IV insulin is not a viable therapeutic
option due to the risk of hypoglycemia. To circumvent the
risk of hypoglycemia and deliver insulin to the brain,
Suzanne Craft from the University of Washington treated
subjects with either early AD or mild cognitive impairment with daily intranasal insulin or placebo. After 21
days, the patients treated with intranasal insulin had better memory-related scores [9]. Another group, from GlaxoSmithKline, also performed a clinical trial of a diabetesrelated drug. They treated 511 AD subjects with the type2 diabetes drug rosiglitazone or placebo for 24 weeks, but
found no clinical improvement on several different tests
[10]. Clearly, further studies are required to determine
how AD is connected to metabolic disorders and whether
drugs that are commonly used to treat metabolic diseases
are beneficial to AD patients.
Finally, one other notable change in this conference was
the plethora of drug company representatives marketing
their formulations of acetylcholinesterase inhibitors and
memantine. While scientists rarely get excited about
increasing numbers of drug salespeople, their presence
was evidence that therapeutics the Alzheimer's research
and pharmaceutical community has been developing for
years are finally coming to the market. Hopefully the therapeutics being marketed at the 2008 ICAD conference in
Chicago will be more numerous and effective.
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